| Date | Title | Description |
| 23.03.2026 | Everest Medicines Accelerates Global Ambitions with Key Acquisitions and Drug Launches | Everest Medicines is reshaping its market footprint. The biopharmaceutical giant secured rights to CARDAMYST™ (etripamil) nasal spray for Greater China. This innovative therapy targets paroxysmal supraventricular tachycardia (PSVT), offerin... |
| 23.03.2026 | Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize CARDAMYST™ (Etripamil) Nasal Spray in Greater China | SHANGHAI, March 23, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of ... |
| 18.03.2026 | Everest Medicines Enters into Letter of Intent with Hasten Biopharmaceuticals (Asia) Limited | SHANGHAI, March 18, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of ... |
| 16.03.2026 | Everest Medicines to Announce 2025 Full-Year Financial Results on March 26, 2026 and Hold Online Earnings Call | SHANGHAI, March 16, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of i... |
| 13.03.2026 | Everest Medicines' Licensing Partner NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study | VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitor
Topline Phase 2a data show VIS-101 provides rapid, robust and durable treatment responses in wet AMD
VIS-101 demons... |
| 10.03.2026 | Everest Medicines to Announce 2025 Full-Year Financial Results on March 26, 2026 | SHANGHAI, March 10, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of i... |
| 09.03.2026 | Everest Medicines Announces Commercial Launch and First Prescription for VELSIPITY® in Mainland China | SHANGHAI, March 9, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of in... |
| 06.02.2026 | Everest Medicines Announces China NMPA Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis | SHANGHAI, Feb. 6, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of inn... |
| 05.02.2026 | Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013 | SHANGHAI, Feb. 5, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of in... |
| 06.01.2026 | Everest Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference | SHANGHAI, Jan. 6, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of in... |
| 31.12.2025 | Everest Medicines Slides After Chinese Drugmaker's Kidney Disease Treatment Is Replicated | (Yicai) Dec. 31 -- Shares of Everest Medicines dropped after the Chinese biopharmaceutical company's immunoglobulin A nephropathy treatment was successfully replicated, with patent protection of innovative drugs becoming a significant issue... |
| 17.12.2025 | Everest Medicines Announces that Licensing Partner LIB Therapeutics has Received U.S. FDA Approval of LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol | SHANGHAI, Dec. 17, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of i... |
| 15.12.2025 | Everest Medicines Announces 2030 Strategy and Increase in Shareholdings by Directors and Substantial Shareholder | SHANGHAI, Dec. 15, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of i... |
| 11.12.2025 | Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten | - Accretive Commercialization Services Agreement covering six mature assets across critical care, cardiovascular, and metabolic disease leveraging Everest's existing commercial organization
- Exclusive Greater China license to develop and c... |
| 21.11.2025 | Everest Medicines Announces First Patient Dosed in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14 | The first patient had received the first dose of EVM14 injection in a global, multi-center Phase I clinical trial of Everest Medicines' Tumor-Associated Antigen (TAA) Cancer Vaccine EVM14 at NEXT Oncology Virginia in the United States, mark... |
| 30.10.2025 | Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders | Everest Medicines acquired an exclusive license to develop, manufacture, and commercialize VIS-101 in Greater China, Singapore, South Korea, and certain Southeast Asian countries.
Under the assigned exclusive license, Everest Medicines will... |
| 30.10.2025 | NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries | NovaBridge subsidiary Visara assigned its exclusive license to Everest Medicines to accelerate the development of potential best-in-class therapy for wet AMD, VIS-101, leveraging Everest Medicines' strong clinical and commercialization expe... |
| 17.10.2025 | I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences | New business model reflects strategic transition to a global biotech platform focused on business development and translational clinical development to accelerate access to innovative medicines for patients worldwide
Intention to pursue a H... |
| 14.10.2025 | Everest Medicines Announces First Patient Enrolled in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14 | SHANGHAI, Oct. 14, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of i... |
| 13.10.2025 | Everest Medicines Announces NMPA Approval of IND Application for Tumor-Associated Antigen Cancer Vaccine EVM14 | EVM14 becomes Everest Medicines' internally developed therapeutic mRNA cancer vaccine to receive IND approvals from both China's National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA).
EVM14, an off-... |
| 10.10.2025 | Everest Medicines Names Fosun Pharma's Ex-Chair to Steer Launch of Its First Personalized Cancer Jab | (Yicai) Oct. 10 -- The former chairman of Chinese pharmaceutical giant Shanghai Fosun Pharmaceutical has been appointed chairman of the board at Everest Medicines as the innovative drugmaker prepares to bring its first personalized cancer v... |
| 09.10.2025 | Everest Medicines Announces Publication of Etrasimod's Asian Multicenter Phase III ENLIGHT UC study (ES101002) Results in The Lancet Gastroenterology & Hepatology | The published study results are from the ENLIGHT UC study (ES101002), a multicenter, randomized, double-blind and placebo-controlled Phase III trial of etrasimod conducted across Asia. The study included a 12-week induction phase followed b... |
| 15.09.2025 | Real-World Evidence of NEFECON® to Be Presented in Seven New Abstracts at the 18th International lgAN Symposium | 7 new NEFECON® real-world evidence abstracts will be presented at the 18th International lgA Nephropathy Symposium (IIgANN 2025).
The newly released results, based on clinical practices at several leading hospitals in China, offer a compreh... |
| 29.08.2025 | Everest Medicines Announces Interim Results for First Half of 2025 | SHANGHAI, Aug. 29, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines a... |
| 25.08.2025 | Everest Medicines Announces Participation in September Investor Conferences | SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of i... |
| 15.08.2025 | Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC | Shanghai, Aug. 15, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of i... |
| 14.08.2025 | Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY® by the Taiwan Food and Drug Administration for the Treatment of Moderately to Severely Active Ulcerative Colitis | SHANGHAI, Aug. 14, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of in... |
| 11.08.2025 | Everest Medicines to Announce 2025 Interim Results on August 29, 2025 | SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of in... |
| 06.08.2025 | Everest Medicines Announces Full Approval of NEFECON® in Taiwan | SHANGHAI, Aug. 6, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of in... |
| 01.08.2025 | Everest Medicines Expands Strategic Investment in I-MAB | - Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash in I-Mab. Inclusive of I-MAB shares already held by Everest, the pro forma ownership will be 16.1%.
- I-Mab's Claudin 18.2 x 4-1BB bispecific antib... |
| 25.07.2025 | Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million | SHANGHAI, July 25, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of in... |
| 04.07.2025 | Everest Medicines Showcases Breakthroughs in Proprietary AI-Powered mRNA Platform at 2025 R&D Day Held in Shanghai | SHANGHAI, July 4, 2025 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative medicines, recently hosted the "202... |
| 04.07.2025 | Everest Medicines targets global expansion with proprietary, AI-driven mRNA platform | After years of building a robust commercial base through in-licensing, Hong Kong-listed biopharmaceutical firm Everest Medicines is entering a new phase of growth: one defined by a “dual-engine” strategy that blends in-house innovation with... |
| 02.07.2025 | Everest Medicines Announces Updated Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy | As of March 21st, 2025, longer follow-up data was collected from the ongoing Ph1b/2a study of EVER001: in Cohort 1, 11 patients completed 52 weeks of follow-up. In Cohort 2, 7 patients completed 52 weeks of follow-up.
The updated data showe... |
| 27.06.2025 | Bridging Health and Technology: The Rise of Innovative Solutions in Antimicrobial Resistance and Wildlife Safety | In the realm of healthcare and technology, two recent developments shine a light on the power of innovation. Everest Medicines has made strides in combating antimicrobial resistance, while EZVIZ has pioneered a wildlife detection algorithm ... |
| 23.06.2025 | Medison and Everest Medicines: Pioneering the Future of Global Biotech | In the ever-evolving landscape of biotechnology, two companies are making significant strides: Medison and Everest Medicines. Both are reshaping the way therapies reach patients, particularly in underserved markets. Their recent development... |
| 23.06.2025 | Everest Medicines Announces Official Publication of the Specifications for Antimicrobial Susceptibility Testing of Eravacycline (2025) | SHANGHAI, June 23, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of i... |
| 20.06.2025 | Everest Medicines Announces Successful Release of First Clinical Batch of Tumor-Associated Antigen Vaccine EVM14 at Jiashan Manufacturing Site | SHANGHAI, June 20, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of i... |
| 10.06.2025 | NEFECON® and EVER001: Pioneering New Frontiers in Renal Disease Treatment | In the realm of renal disease, hope often feels like a distant star. Yet, recent breakthroughs from Everest Medicines illuminate the path forward. At the 62nd European Renal Association Congress (ERA 2025), two innovative treatments, NEFECO... |
| 09.06.2025 | Everest Medicines Presents Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of Novel BTK Inhibitor EVER001 at the 62nd Congress of the European Renal Association | EVER001 is a covalent reversible BTK inhibitor with potentially best-in-class characteristics for the treatment of primary membranous nephropathy (pMN) and other autoimmune renal diseases, including IgA nephropathy (IgAN), minimal change di... |
| 06.06.2025 | NEFECON®: New Results at ERA 2025 Demonstrate Treatment Benefit of the 'Treat Early' Strategy | Two new studies on NEFECON® demonstrate its treatment benefit in the "Treat Early" strategy for IgA nephropathy (IgAN), providing robust support for the new disease management strategy: "Treat the Cause, Treat Early, Treat Al... |
| 23.05.2025 | Everest Medicines Announces NEFECON® Inclusion in China's Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review) | SHANGHAI, May 23, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of in... |
| 07.05.2025 | Everest Medicines Announces NMPA Full Approval of NEFECON® for the Treatment of Primary Immunoglobulin A nephropathy (IgAN) in Adults at Risk of Disease Progression | SHANGHAI, May 7, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of inn... |
| 30.04.2025 | Everest Medicines Announces New Drug Application Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis in Hong Kong | SHANGHAI, April 30, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of ... |
| 28.04.2025 | Everest Medicines: A New Chapter Without the "B" Marker | Everest Medicines is shedding its "B" marker. This change, effective May 2, 2025, marks a significant milestone for the biopharmaceutical company. The "B" designation, which indicated a lower market capitalization, will ... |
| 28.04.2025 | Everest Medicines Announces the "B" Marker Removal from Company's Stock Code, Effective May 2, 2025 | SHANGHAI, April 28, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of ... |
| 22.04.2025 | Everest Medicines Announces Approval of "B" Marker Removal from Company's Stock Code by the Hong Kong Stock Exchange | SHANGHAI, April 22, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of ... |
| 27.03.2025 | Everest Medicines: Pioneering mRNA Cancer Vaccines and Financial Growth in 2024 | Everest Medicines is carving a niche in the biopharmaceutical landscape. With its recent FDA clearance for EVM14, an mRNA-based cancer vaccine, the company is poised to change the game in oncology. This breakthrough is not just a milestone;... |
| 26.03.2025 | Everest Medicines Announces Financial Results for Full Year Ended December 31, 2024 | SHANGHAI, March 26, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of i... |
| 26.03.2025 | CBC Group hits first close on China’s largest healthcare buyout fund | CBC Group has raised over RMB 7 billion (USD 980 million) in the first close of its inaugural RMB-denominated healthcare buyout fund, with a target size of RMB 10 billion (USD 1.4 billion). The fund, which is now the largest of its kind in ... |
| 24.03.2025 | Everest Medicines Announces FDA Clearance of IND Application for Tumor-Associated Antigen Vaccine EVM14 | EVM14 received U.S. FDA clearance for its IND application, becoming Everest's first internally discovered program, and the first mRNA therapeutic cancer vaccine to be cleared for global clinical development.
Preclinical highlights：
EVM14 in... |
| 07.03.2025 | Everest Medicines Takes a Bold Step in Cancer Treatment with EVM16 | In the world of cancer treatment, hope often feels like a flickering candle in a storm. But Everest Medicines has just lit a new flame. The company recently announced a significant milestone: the first patient has been dosed with EVM16, its... |
| 06.03.2025 | Everest Medicines Announces First Patient Dosed with EVM16, Its First Internally Developed Personalized mRNA Cancer Vaccine | The first patient has been dosed with EVM16 at Peking University Cancer Hospital, marking a major milestone as Everest's proprietary AI-based tumor neoantigen prediction algorithm and clinically validated mRNA platform progress into human t... |
| 01.03.2025 | Etrasimod: A New Dawn for Ulcerative Colitis Treatment | In the realm of biopharmaceuticals, innovation is the lifeblood. Everest Medicines has recently unveiled promising data on etrasimod, a drug that could redefine treatment for ulcerative colitis (UC). This once-daily oral medication has show... |
| 28.02.2025 | Everest Medicines to Hold Investor Calls with Updates on mRNA Therapeutic Vaccine Programs | SHANGHAI, Feb. 28, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative phar... |
| 26.02.2025 | Everest Medicines Presents Complete Maintenance Period Data for Etrasimod at ECCO 2025 | Data confirms significant clinical and endoscopic benefits of etrasimod 2mg after 40 weeks of maintenance treatment
Etrasimod demonstrates robust efficacy across multiple endpoints, including mucosal healing, endoscopic normalization, and h... |
| 25.02.2025 | Everest Medicines to Announce Full-Year 2024 Financial Results on March 26, 2025 | SHANGHAI, Feb. 25, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of in... |
| 18.12.2024 | Everest Medicines Announces the First Prescription of VELSIPITY® in the Greater Bay Area, Officially Benefiting Mainland China Patients | SHANGHAI, Dec. 18, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of in... |
| 17.12.2024 | VELSIPITY®: A New Dawn for Ulcerative Colitis Treatment in Asia | In the realm of biopharmaceuticals, every breakthrough feels like a beacon of hope. Everest Medicines has recently ignited this hope with its drug, VELSIPITY® (etrasimod). This innovative treatment for moderately to severely active ulcerati... |
| 17.12.2024 | Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY® by the National Medical Products Administration of China for the Treatment of Moderately to Severely Active Ulcerative... | SHANGHAI, Dec. 17, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of in... |
| 12.12.2024 | Everest Medicines Announces the First Prescription of VELSIPITY® Issued in Macau, Officially Beginning to Benefit Asian Patients | SHANGHAI, Dec. 12, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of in... |
| 04.12.2024 | Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy | Patients in the low-dose cohort who have completed 36 weeks of treatment, 9 out of 11 (81.8%) achieved overall clinical remission and 10 out of 11 (91%) achieved immunological complete remission.
In the high dose cohort, 6 out of 7 (85.7%) ... |
| 02.12.2024 | Centric360's Acquisition of HCS: A New Chapter in IT Services | In the ever-evolving landscape of technology, acquisitions are the lifeblood of growth. The recent acquisition of HCS, a managed IT services provider based in Waterford, by Centric360 marks a significant shift in the Irish IT sector. This d... |
| 02.12.2024 | Everest Medicines Announces Acceptance of VELSIPITY® New Drug Application in Hong Kong | SHANGHAI, Dec. 2, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of inn... |
| 28.11.2024 | Everest Medicines Announces NEFECON®, the World's First Approved Treatment for IgA Nephropathy, is Included in China's National Reimbursement Drug List | SHANGHAI, Nov. 28, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of in... |
| 27.11.2024 | Everest Medicines to Hold Investor Calls on Data Results from EVER001 Phase 1b/2a Clinical Study in Primary Membranous Nephropathy | SHANGHAI, Nov. 27, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of in... |
| 24.11.2024 | Everest Medicines: Pioneering Solutions in the Battle Against Disease | In the ever-evolving landscape of biopharmaceuticals, Everest Medicines stands as a beacon of hope. This Shanghai-based company is on a mission to tackle some of the most pressing health challenges in Asia. With innovative therapies like er... |
| 22.11.2024 | Two In Vitro Studies on Eravacycline (XERAVA®) Presented at IDWeek, Demonstrating Its Sustained and Robust Antimicrobial Activity | SHANGHAI, Nov. 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of i... |
| 19.11.2024 | Everest Medicines Announces NEFECON® Has Received Full Approval from South Korea's Ministry of Food and Drug Safety (MFDS) for the Treatment of Primary IgA Nephropathy | SHANGHAI, Nov. 19, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of in... |
| 25.10.2024 | Everest Medicines Announces the Launch of VELSIPITY® in the Guangdong-Hong Kong-Macau Greater Bay Area, Offering a New Option for Moderately to Severely Active Ulcerative Colitis Patients | SHANGHAI, Oct. 25, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of in... |
| 23.10.2024 | NEFECON®: A Beacon of Hope for IgA Nephropathy Patients in Asia | In the realm of biopharmaceuticals, few developments shine as brightly as the recent approval of NEFECON® by the Taiwan Food and Drug Administration (TFDA). This groundbreaking treatment, designed for primary immunoglobulin A nephropathy (I... |
| 22.10.2024 | Everest Medicines Announces Positive Results of Complete Chinese Subpopulation Data from the NEFECON® Global Phase 3 NefIgArd Clinical Trial Published in "Kidney 360" Magazine | SHANGHAI, Oct. 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of in... |
| 21.10.2024 | Everest Medicines Announces Taiwan TFDA Approval of NEFECON® for the Treatment of Primary IgA Nephropathy | SHANGHAI , Oct. 21, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of i... |
| 29.08.2024 | Everest Medicines: Climbing New Heights in Biopharmaceuticals | Everest Medicines is scaling new heights in the biopharmaceutical landscape. The company recently announced its interim results for the first half of 2024, showcasing impressive growth and strategic advancements. With a focus on innovative ... |
| 28.08.2024 | Everest Medicines Announces Interim Results for First Half of 2024 | SHANGHAI, Aug. 28, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines a... |
| 27.08.2024 | Everest Medicines Announces Interim Results for First Half of 2024 | SHANGHAI, Aug. 27, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines a... |
| 22.08.2024 | Everest Medicines Announces the Initiation of an Investigator-Initiated Clinical Trial (IIT) for Personalized mRNA Cancer Vaccine Program EVM16 | SHANGHAI, Aug. 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of in... |
| 14.08.2024 | Calliditas and Asahi Kasei: A Strategic Dance in the Biopharma Arena | In the fast-paced world of biopharmaceuticals, every move counts. Calliditas Therapeutics AB, a Swedish biopharma company, recently unveiled its interim report for the first half of 2024. The numbers tell a story of growth, challenges, and ... |
| 13.08.2024 | Calliditas Interim Report January to June 2024 | Calliditas Interim Report January to June 2024
Tue, Aug 13, 2024 07:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX):
April to June 2024 (compared to April to June 2023) Net sales amounted to SEK... |
| 06.08.2024 | Everest Medicines to Announce 2024 Interim Results on August 28, 2024 | SHANGHAI, Aug. 6, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of inn... |
| 22.07.2024 | Everest Medicines Announces First Chinese Patient Dosed in Global Phase 2b PALIZADE Trial of Zetomipzomib in Lupus Nephritis | SHANGHAI, July 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of in... |
| 18.07.2024 | Everest Medicines Announces Official Acceptance Granted on NEFECON® Supplementary Application by China National Medical Products Administration | SHANGHAI, July 18, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of in... |
| 15.07.2024 | Everest Medicines Announces Positive Topline Results from Maintenance Period of Etrasimod Phase 3 Clinical Trial Conducted in Asia for the Treatment of Moderately-to-Severely Active Ulcerative Colitis | SHANGHAI, July 15, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of in... |
| 23.05.2024 | Calliditas Q1 report, January – March 2024 | Calliditas Q1 report, January – March 2024
Thu, May 23, 2024 07:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq Stockholm: CALTX):
Target market expansion following full approval in the US
JANUARY – MARCH 2024 (COMPARED TO JAN... |
| 14.05.2024 | Calliditas’ Partner Everest Medicines Starts Commercial Launch of Nefecon in China | Calliditas’ Partner Everest Medicines Starts Commercial Launch of Nefecon in China
Tue, May 14, 2024 13:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announces that its pa... |
| 14.05.2024 | Everest Medicines Announces Commercial Launch and First Prescription for NEFECON® in Mainland China | SHANGHAI, May 14, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of inn... |
| 08.05.2024 | Everest Medicines Announces New Drug Application Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis in Macau | SHANGHAI, May 8, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative me... |
| 02.05.2024 | Everest Medicines Announces Hong Kong Department of Health Approval of Nefecon® for the Treatment for Primary IgA Nephropathy in Adult Patients | SHANGHAI, May 2, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company") announced that the Hong Kong Department of Health had approved Nefecon® for the treatment of primary immunoglobulin A ne... |
| 28.03.2024 | Everest Medicines Announces Financial Results for Full Year Ended December 31, 2023 | SHANGHAI, March 28, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of i... |
| 20.03.2024 | Everest Medicines Announces Singapore Health Sciences Authority Approves NEFEGAN® for the Treatment of Primary IgA Nephropathy in Adult Patients | SHANGHAI, March 20, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative... |
| 18.03.2024 | Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer | SHANGHAI, March 18, 2024 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovativ... |
| 12.03.2024 | Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon® | SHANGHAI, March 12, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company")'s licensing partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") annou... |
| 11.03.2024 | Everest Medicines Announces Acceptance of VELSIPITY® New Drug Application in Macau | -- Macau is on course to become the first of Everest's Asian territories to get etrasimod approval
-- Can provide access to patients in China's Greater Bay area and rest of Asia
SHANGHAI, March 11, 2024 /PRNewswire/ -- Everest Medicines (HK... |
| 06.03.2024 | Everest Medicines to Announce Full-Year 2023 Financial Results on March 28, 2024 | SHANGHAI, March 6, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines a... |
| 27.02.2024 | Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis | SHANGHAI, China and SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (Nasdaq: KZR) announced today that the Center for Drug Evaluation (CDE) of China's National Medica... |
| 22.02.2024 | Everest Medicines' Partner Pfizer Announces European Commission Approves VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis | --VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU--
SHANGHAI, Feb. 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or th... |
| 21.02.2024 | Everest Medicines' Licensing Partner Venatorx Pharmaceuticals Announces Publication of Positive Results from Cefepime-Taniborbactam's Phase 3 CERTAIN-1 Study in New England Journal of Medicine | --Cefepime-taniborbactam was superior to meropenem for the composite efficacy endpoint with composite efficacy sustained at late follow-up visit--
SHANGHAI, Feb. 21, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK)'s licensing partner,... |
| 19.02.2024 | Everest Medicines Announces Termination of Collaboration Agreements with Providence | -Everest will continue to develop self-discovered products utilizing the mRNA platform-
SHANGHAI, Feb. 19, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company f... |
| 22.01.2024 | Everest Medicines Announces 2023 Revenue Expected to be Between RMB124 Million and RMB126 Million | SHANGHAI, Jan. 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines a... |
| 21.12.2023 | Everest Medicines' Partner Calliditas Therapeutics Announces Nefecon® the Only FDA-approved Treatment for IgA Nephropathy to Significantly Slow Kidney Function Decline | SHANGHAI, Dec. 21, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company")'s licensing partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") announ... |
